Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study

医学 结直肠癌 化疗 肿瘤科 随机对照试验 内科学 癌症
作者
Bogumiła Ciseł,Lucyna Pietrzak,Wojciech Michalski,Lucjan Wyrwicz,Andrzej Rutkowski,Ewa Kosakowska,Anna Cencelewicz,Mateusz Spałek,Wojciech Polkowski,M. Jankiewicz,Roman Styliński,Marek Bębenek,Bartosz Kapturkiewicz,Adam Maciejczyk,Jacek Sadowski,J. Zygulska,W. Zegarski,Michał Jankowski,Manuela Las‐Jankowska,Z. Toczko
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:30 (8): 1298-1303 被引量:291
标识
DOI:10.1093/annonc/mdz186
摘要

BackgroundThis trial evaluated whether preoperative short-course radiotherapy and consolidation chemotherapy (CCT) were superior to chemoradiation in rectal cancers with clinical (c)T4 or fixed cT3. Previously, we reported early results showing no differences in the radical surgery rate (primary end point). In the short-course/CCT group, we observed lower acute toxicity of preoperative treatment and better overall survival (OS). We updated results to determine whether the benefit in OS was sustained and to evaluate late complications.Patients and methodsPatients with cT4 or fixed cT3 rectal cancer were randomized either to preoperative 5 × 5 Gy and three cycles of FOLFOX4 or to chemoradiation (50.4 Gy with bolus 5-Fu, leucovorin and oxaliplatin).ResultsPatients (N = 515) were eligible for analysis, 261 in the short-course/CCT group and 254 in the chemoradiation group. The median follow-up was 7.0 years. The difference in OS was insignificant [hazard ratio (HR) 0.90; 95% confidence interval (CI) 0.70–1.15; P= 0.38). However, the difference in early OS favouring short-course/CCT previously reported was observed again, being 9% at 3 years (95% CI 0.5% to 17%). This difference disappeared later; at 8 years OS was 49% in both groups. There was no difference in disease-free survival (HR 0.95; 95% CI 0.75–1.19; P= 0.65) at 8 years 43% versus 41% in the short-course/CCT group versus the chemoradiation group, respectively. The corresponding values for cumulative incidences of local failure and distant metastases did not differ and were HR = 1.08, 95% CI 0.70–1.23, P= 0.60, 35% versus 32% and HR = 1.10, 95% CI 0.68–1.23, P= 0.54, 36% versus 34%, respectively. The rate of late complications was similar (P= 0.66), grade 3+ being 11% versus 9% in the short-course/CCT group versus the chemoradiation group, respectively.ConclusionThe superiority of preoperative short-course/CCT over chemoradiation was not demonstrated.Clinical trial numberThe trial is registered as ClinicalTrials.gov number NCT00833131.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
沐阳wyr发布了新的文献求助10
刚刚
科目三的应助被成就的艳一采纳,获得10
1秒前
研友_VZG7GZ的应助被徐礼杨采纳,获得10
1秒前
领导范儿的应助被聪明的傲白采纳,获得10
2秒前
1930848完成签到 ,获得积分10
2秒前
Super_Tina发布了新的文献求助50
2秒前
2秒前
cwf关注了科研通微信公众号
2秒前
胖鱼发布了新的文献求助10
3秒前
小曾完成签到,获得积分10
3秒前
kylin发布了新的文献求助10
4秒前
yyydmhsj完成签到 ,获得积分10
4秒前
哈哈哈完成签到,获得积分10
4秒前
5秒前
smirys发布了新的文献求助10
5秒前
6秒前
shijie发布了新的文献求助10
6秒前
一点点粽子完成签到,获得积分10
6秒前
小周小周发布了新的文献求助10
6秒前
~~~~发布了新的文献求助10
7秒前
村雨完成签到,获得积分10
7秒前
谢昊宸完成签到,获得积分10
7秒前
xyliu257完成签到,获得积分20
7秒前
何宗友完成签到,获得积分10
8秒前
molihuakai的应助被腼腆的凡波采纳,获得30
8秒前
shiyan完成签到,获得积分10
8秒前
9秒前
shubido完成签到 ,获得积分10
9秒前
pp发布了新的文献求助10
9秒前
10秒前
优秀的祥发布了新的文献求助10
10秒前
111发布了新的文献求助10
10秒前
大宝剑2号发布了新的文献求助10
10秒前
10秒前
10秒前
YR完成签到 ,获得积分10
10秒前
11秒前
11秒前
11秒前
大个的应助被Sylvia77xr采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Energie-Contracting 1500
Mathematical models in hydrology 1000
Klimaschutzrecht durch den Energiesektor im Mehrebenensystem – Ein Rechtsvergleich 1000
Oncology Clinical Trials: Successful Design, Conduct, and Analysis, Second Edition 800
Erzählte Gnade 500
Butadiene hydroxytelechelic oligomers PBHT 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8082364
求助须知:如何正确求助?哪些是违规求助? 9497752
关于积分的说明 21403042
捐赠科研通 7650490
什么是DOI,文献DOI怎么找? 3401795
关于科研通互助平台的介绍 2530958
邀请新用户注册赠送积分活动 2440494